ArticleNature communications2019
An African Salmonella Typhimurium ST313 sublineage with extensive drug-resistance and signatures of host adaptation.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Invasive non-typhoidal Salmonella infections in China (1961-2024): a retrospective systematic analysis of multicentre case reports.Journal of global health · 2026Pooled it
- Prevalence and distribution of non-typhoidalEpidemiology and infection · 2023Pooled it
- Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis.The Lancet. Infectious diseases · 2022Pooled it
- Incidence of non-typhoidal Salmonella invasive disease: A systematic review and meta-analysis.The Journal of infection · 2021Pooled it
- Public health data collected by PulseNet support a role forMicrobiology spectrum · 2026Article
- In vitro antibacterial properties of selected medicinal plants used by traditional healers for gastrointestinal disorders in the Heban-Arsi and Kofale districts of Southern Ethiopia.BMC complementary medicine and therapies · 2026Article
- Mobile Genetic Elements Associated with Antimicrobial Resistance Across One Health Interfaces in Africa: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Epidemiology and genomics of azithromycin-resistant extensively drug-resistantAntimicrobial agents and chemotherapy · 2026Article
- Host adaptation inApplied and environmental microbiology · 2026Review
- Distinct genomic trajectory among invasive Salmonella Typhimurium ST313 infections.Nature communications · 2026Article
- Persistence of non-typhoidalFrontiers in microbiology · 2026Review
- Development of a GMMA-based candidate vaccine against invasive nontyphoidalFrontiers in immunology · 2026Article
- Genomic surveillance reveals escalating antimicrobial resistance and plasmid diversity in clinicalFrontiers in microbiology · 2026Article
- Circulation of Salmonella spp. between humans, animals and the environment in animal-owning households in Malawi.Nature communications · 2025Article
- Diversity of Salmonella enterica isolates from urban river and sewage water in Blantyre, Malawi.PLoS neglected tropical diseases · 2025Article
- PgtE protease enables virulentmBio · 2025Article
- Genomic census of invasive nontyphoidal Salmonella infections reveals global and local human-to-human transmission.Nature medicine · 2025Article
- Prevalence ofChina CDC weekly · 2025Article
- AInfection and immunity · 2025Article
- Avian-specificeLife · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 4 countries.
Funding
Abstract
Bloodstream infections by Salmonella enterica serovar Typhimurium constitute a major health burden in sub-Saharan Africa (SSA). These invasive non-typhoidal (iNTS) infections are dominated by isolates of the antibiotic resistance-associated sequence type (ST) 313. Here, we report emergence of ST313 sublineage II.1 in the Democratic Republic of the Congo. Sublineage II.1 exhibits extensive drug resistance, involving a combination of multidrug resistance, extended spectrum β-lactamase production and azithromycin resistance. ST313 lineage II.1 isolates harbour an IncHI2 plasmid we name pSTm-ST313-II.1, with one isolate also exhibiting decreased ciprofloxacin susceptibility. Whole genome sequencing reveals that ST313 II.1 isolates have accumulated genetic signatures potentially associated with altered pathogenicity and host adaptation, related to changes observed in biofilm formation and metabolic capacity. Sublineage II.1 emerged at the beginning of the 21st century and is involved in on-going outbreaks. Our data provide evidence of further evolution within the ST313 clade associated with iNTS in SSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.